Advicenne reports its First Half Financial results as of June 30, 2023 and updates on its activities

Paris - Advicenne (Euronext Growth Paris ALDVI - FR0013296746), a specialty pharmaceutical company dedicated to the development and commercialization of innovative treatments for those suffering from rare renal diseases, today reports its semi-annual financial results as of June 30, 2023, as approved on September 8, 2023, by the Board of Directors.

Didier Laurens, Chief Executive Officer of Advicenne, commented: I am particularly satisfied with Advicenne s transformation into a commercial company, which has led to accelerating sales growth in the first half. We now cover the whole of Europe thanks to our various partnerships, and we have convincing long-term clinical data for our main product Sibnayal. These elements are supporting our prospects for continued acceleration in growth. In this context, we are today announcing a capital increase with preferential subscription rights for shareholders. This operation has been made possible thanks to the strong support of our long-term shareholders, Bpifrance and Cemag Invest, and in respect of the investors who have been with us for several years. This financing will enable us to pursue our development and thus giving us sufficient means to reach operational profitability. I am particularly pleased for the patients and those around them, the Advicenne team for its daily commitment and all our shareholders.

About Advicenne

Advicenne (Euronext: ALDVI) is a specialty pharmaceutical company founded in 2007, specializing in the development of innovative treatments in Nephrology. Its lead product Sibnayal (ADV7103) has received its Marketing Approval for distal renal tubular acidosis in EU and GB. ADV7103 is currently in late-stage development in cystinuria in Europe and in dRTA and cystinuria in the US and in Canada. Headquartered in Paris, Advicenne, listed on the Euronext Paris stock exchange since 2017, has now been listed on Euronext Growth Paris since its transfer on March 30, 2022.

Contact:

Didier Laurens

Tel: [phone]

Email: [e-mail]

Disclaimer

This press release contains certain forward-looking statements concerning Advicenne group and its business, including its prospects and product candidate development. Such forward-looking statements are based on assumptions that Advicenne considers to be reasonable. However, there can be no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the 2022 Universal Registration Document filed with the French financial market authority on April 28, 2023 (a copy of which is available on www.advicenne.com) and to the development of economic conditions, financial markets and the markets in which Advicenne operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Advicenne or not currently considered material by Advicenne. The occurrence of all or part of such risks could cause actual results, financial conditions, performance, or achievements of Advicenne to be materially different from such forward-looking statements. Advicenne expressly declines any obligation to update such forward-looking statements.

(C) 2023 Electronic News Publishing, source ENP Newswire